Patient dies in BMS autoimmune CAR-T trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bristol Myers Squibb reported a patient death in a Phase 1 CAR-T trial for multiple sclerosis, following unresolved motor symptoms and septic pneumonia after treatment with a potent immunosuppressant
- The patient developed motor symptoms that did not respond to standard autoimmune therapies before receiving the investigational CAR-T therapy
- Bristol Myers Squibb stated the patient had been treated for multiple prior complications, making it difficult to isolate the root cause of the fatal event
- The trial involves an investigational CAR-T therapy, adding to safety concerns in the emerging field of autoimmune applications for this technology
Why it matters: This death introduces uncertainty into the development of CAR-T therapies for autoimmune diseases, where safety profiles are less established than in oncology. With prior complications clouding causality, regulators and investors may demand more rigorous risk assessment before advancing similar trials, potentially slowing the field’s expansion despite its therapeutic promise.
Ask SkimNews
